Quinnova Pharmaceuticals Inc., of Newtown, Pa., appointed Christopher Hensby senior vice president of research and development.

Regulus Therapeutics LLC, of Cambridge, Mass., appointed Stelios Papadopoulos to its board.

RFS Pharma LLC, of Atlanta, appointed Marc M. Giradot director of business development.

Rib-X Pharmaceuticals Inc., of New Haven, Conn., named Joseph Amprey to its board.

Seattle Genetics Inc., of Bothell, Wash., named Elaine Waller senior vice president of regulatory affairs and appointed Christopher Pawlowicz senior vice president of human resources. It also named Jonathan Drachman vice president of early clinical development.

Sinobiomed Inc., of Shanghai, China, named Brent Suen director of strategic development.

Somnus Therapeutics Inc., of Bedminster, N.J., appointed Gary Cupit, Linda C. Hogan, David Ramsay and Jack W. Britts to its board.

Sucampo Pharmaceuticals Inc., of Bethesda, Md., appointed Masanori Ueda senior vice president of business development at its Japanese subsidiary.

Synosia Therapeutics, of Basel, Switzerland, appointed Hans-Rudolf Olpe vice president of neuropharmacology.

Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, added Tammy Mullarky as vice president of strategic planning and business development and named Peter Lutwyche vice president of pharmaceutical development.

Tengion Inc., of East Norriton, Pa., appointed Brian J. G. Pereira to its board.

TheraGenetics Ltd., of Cambridge, Mass., appointed Robert N.McBurney executive vice president.